Related Experiment Video

Updated: May 31, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far

Patricia A Tang1, Michael M Vickers, Daniel Y C Heng

  • 1Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331-29th Street North West, Calgary, Alberta, Canada.

Hematology/Oncology Clinics of North America
|July 19, 2011
PubMed

Insights

New prognostic tools are needed for metastatic renal cell carcinoma (RCC) treatment. This review examines current clinical models and molecular biomarkers for better therapy selection in RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Clinical Medicine

Background:

  • Current metastatic renal cell carcinoma (RCC) treatment involves targeting vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways.
  • These targeted therapies have significantly advanced RCC treatment over the last five years.
  • The evolving treatment landscape necessitates improved methods for predicting patient outcomes and guiding therapy choices.

Purpose of the Study:

  • To review existing clinical prognostic models for metastatic renal cell carcinoma (RCC).
  • To examine molecular biomarkers relevant to RCC prognosis and treatment selection.
  • To highlight the need for advanced predictive and prognostic tools in RCC management.

Main Methods:

  • Literature review of clinical prognostic models in RCC.
  • Analysis of studies on molecular biomarkers in renal cell carcinoma.
  • Synthesis of current data on predictive and prognostic tools for RCC.

Main Results:

  • Established clinical models exist for predicting RCC patient outcomes.
  • Various molecular biomarkers show potential for prognostic and predictive value in RCC.
  • There is a clear need for integrating these tools into clinical practice.

Conclusions:

  • Advanced clinical and molecular tools are crucial for optimizing metastatic renal cell carcinoma (RCC) therapy selection.
  • Prognostic models and biomarkers can aid in patient counseling and clinical trial design.
  • Further research is needed to validate and implement these tools for improved RCC patient care.

More Related Videos

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...